A recent study suggests that individuals who discontinue blockbuster slimming jabs like semaglutide or tirzepatide may regain reduced body mass at a significantly accelerated pace than those who halt conventional diet and exercise plans.
Findings released in a major medical journal shows that while overweight people often shed about a fifth of their total mass while undergoing treatment, the weight comes back at an average rate of 0.8 kg per month upon discontinuation.
"Users using such treatments must be aware of the potential of quick rebound weight gain when the therapy ends," stated expert Dr. Susan Jebb.
This pace of regain implies a reversion to starting weight in about a year and a half.
Analyzing Therapies
The research, which examined 37 of trials involving thousands of patients, compared the effects of GLP-1 agonists with conventional dieting.
Researchers emphasize that individuals who shed pounds through dieting typically see a less rapid weight regain—perhaps 100 grams monthly—post-intervention.
Explaining the Quick Rebound
Doctors propose the mode of action of the jabs is key to understanding the accelerated rebound.
GLP-1 drugs copy a body's own chemical called GLP-1, which helps regulate feelings of fullness.
"Sustained high doses of the hormone levels far above than normal could lead to the body to generate a reduced amount of its own natural GLP-1, and could diminish responsiveness to its actions," explained Dr. Adam Collins, a dietetics expert.
"Withdrawal of this medication means appetite is unsuppressed, making binge eating a significant risk."
A Lifelong Condition?
The NHS recommend the jabs for individuals with obesity-related medical conditions, accompanied by prescribed lifestyle changes.
Many experts say that, considering the significant potential of weight regain, the therapy is often long-term.
This view is reinforced by pharmaceutical companies, who say that the results "emphasize the persistent nature of excess weight," similar to managing diseases like high blood pressure.
User Accounts
Users who have discontinued the jabs describe a sudden return of hunger.
"I experienced a trigger flipping and you become extremely hungry," said a patient.
This challenge is worsened if individuals have not established lasting lifestyle or habit changes during treatment.
Widespread Adoption
Survey data suggest that millions of adults in the UK have used these injections in the past year, with desire being substantial.
- Use is greater among women than men.
- The middle-aged demographic shows the greatest usage rates.
- Many access the medications through private healthcare rather than the NHS.
In conclusion, researchers emphasize that while GLP-1 drugs are potent tools for weight loss, they are not a standalone fix and maintained weight loss likely depends on ongoing behavioural support.
